[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou JOYO Pharma Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,74,105,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100584874","phase-2-study-of-jyp0015-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras-100584874",false,"NCT06895031","Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","A Multi-center, Open-label, Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation","STAR","Inclusion Criteria:\n\n1. Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.\n2. Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment\n3. Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1\n4. Adequate organ function\n\nExclusion Criteria:\n\n1. Presence of central nervous system (CNS) metastases; however, subjects with previously treated brain metastases may be enrolled if clinically stable.\n2. Gastrointestinal (GI) disorders that may interfere with drug administration\u002Fabsorption, including but not limited to: Dysphagia or inability to swallow tablets， Malabsorption syndrome，Refractory nausea, vomiting, or diarrhea，Chronic GI diseases (e.g., Crohn's disease, ulcerative colitis)\n3. Congestive heart failure with New York Heart Association (NYHA) functional class ≥II or left ventricular ejection fraction (LVEF) \\\u003C50%.\n4. Any other condition deemed by the investigator to potentially compromise study outcomes or lead to premature termination, including but not limited to: Alcohol or substance abuse，Concurrent severe medical conditions (e.g., psychiatric disorders requiring active treatment)， Familial or social circumstances that may affect patient safety, compliance, or study data collection.","ALL","18 Years","75 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.",[28,29,30,31],"Solid Tumor","Pancreatic Ductal Adenocarcinoma (PDAC)","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)",[33,34,35],"PDAC","NSCLC","CRC","RECRUITING","2026-03-04",{"date":39,"type":40},"2026-03-06","ACTUAL",{"date":42,"type":40},"2025-03-31",{"date":44,"type":22},"2026-12-31",{"name":46,"class":47},"Guangzhou JOYO Pharma Co., Ltd","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100604811","phase-3-jyp0322-versus-platinum-based-doublet-chemotherapy-in-ros1-positive-patients-previously-treated-with-ros1-tkis-100604811","NCT07154368","JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.","A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of JYP0322 Versus Platinum-Based Chemotherapy in ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Previously Treated With ROS1-TKI Therapy.","Inclusion Criteria:\n\n* Key Inclusion Criteria\n\n  * Subjects with histologically or cytologically documented NSCLC.\n  * Locally advanced or metastatic ROS1 fusion positive NSCLC.\n  * Prior one or two ROS1-TKI(s) Treatment.\n  * World Health Organization (WHO) performance status 0-1.\n  * Life expectancy of at least 3 months.\n  * At least one measurable lesion according to RECISIT 1.1.\n\nExclusion Criteria:\n\n* Key Exclusion Criteria:\n\n  * Current participation in another therapeutic clinical trial.\n  * Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.\n  * A history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug.\n  * All acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade more than 1.\n  * Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.\n  * Known active infe",{"count":57,"type":22},207,[59],"PHASE3","The primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive disease (PD), while also have the choice to pursue with other drugs after discussing with their physicians.",[62],"Non Small Cell Lung Cancer",[64],"Lung Cancer","NOT_YET_RECRUITING","2025-09-17",{"date":68,"type":40},"2025-09-19",{"date":70,"type":22},"2025-09-23",{"date":72,"type":22},"2029-12-31",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100525931","phase-1-phase-i-study-of-jyp0322-in-ros1-fusion-positive-solid-tumors-100525931","NCT06128148","Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors","JYP0322","Key Inclusion Criteria\n\n* Adult patients age 18 years or older.\n* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a ROS1 molecular fusion.\n* Measurable disease according to RECIST version 1.1\n* Life expectancy of at least 3 months\n* Other protocol specified criteria\n\nKey Exclusion Criteria:\n\n* Current participation in another therapeutic clinical trial.\n* Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.\n* A history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug.\n* Known active infections (bacterial, viral including HIV positivity).\n* Other protocol specified criteria",{"count":83,"type":22},101,[85],"PHASE1","An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced\u002Fmetastatic solid tumors .",[88,89,90,91],"Protein Kinase Inhibitors","Other Protocol Specified Criteria","Lung Neoplasms","Brain Neoplasms",[93,94,95,96],"ROS1 Fusions","ROS1 Gene Rearrangements","Primary brain tumors","ROS1","2025-07-09",{"date":99,"type":40},"2025-07-14",{"date":101,"type":40},"2022-05-04",{"date":103,"type":22},"2027-12-30",{"name":46,"class":47},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":48},"100569691","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-jyp0061-in-patients-with-acute-neuromyelitis-spectrum-disease-nmosd-100569691","NCT06697535","A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)","Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD): a Multicenter, Randomized, Open-label, Positive-controlled, Two-stage Exploratory Phase 2 Trial","Inclusion Criteria:\n\n* Neuromyelitis spectrum disease (NMOSD) patients according to 2015 International consensus diagnostic criteria.\n* Positive Aquaporin 4 immunoglobulin G (AQP4-IgG)\n* Patients with acute NMOSD\n* Female serum pregnancy test results were negative at the time of screening, subject (including partner) had no child-rearing plan and voluntarily adopted double contraceptive (non-oral contraceptives) within 6 months from screening to the last study drug administration, and had no sperm\u002Fegg donation plan;\n* Have fully understood this study, voluntarily participate in the experiment, and voluntarily sign the written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Suspected or clear allergy to similar ingredients or any ingredient in the study drug, or allergic constitution;\n* Symptoms improved in the acute phase before the study drug was used;\n* Unable to complete MRI or gadolinium enhanced examination;","65 Years",{"count":114,"type":22},35,[25],"The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients. Participants will be treated with low-dose JYP0061 in combination with reduced dose glucocorticoids or standard dose glucocorticoids or high-dose JYP0061. Efficacy and safety evaluations will be conducted according to the protocol.",[118],"Neuromyelitis Optica Spectrum Disorders","2024-11-19",{"date":121,"type":40},"2024-11-20",{"date":123,"type":40},"2023-05-24",{"date":125,"type":22},"2026-07-30",{"name":46,"class":47},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":48},"100525714","phase-2-sc1011-twice-daily-vs-placebo-in-patients-diagnosed-with-idiopathic-pulmonary-fibrosis-ipf-100525714","NCT06125327","SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)","A Randomized, Double-blind, Placebo-controlled Phase II\u002FIII Trial Evaluating the Efficacy and Safety of Sufenidone (SC1011) Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF).","Inclusion Criteria:\n\n* Ability to understand and sign written informed consent.\n* The diagnosis time of IPF before enrollment was less than 5 years.\n* Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF.\n* Dlco (corrected for Hb): 30%-90% predicted of normal.\n* FVC\\>= 50% predicted of normal.\n\nExclusion Criteria:\n\n* Forced expiratory volume in one second (FEV1)\u002FFVC ratio \\\u003C0.7 after administration of bronchodilator at Screening\n* Expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the United States, on a lung transplant waiting list at randomization.\n* Known explanation for interstitial lung disease\n* History of asthma or chronic obstructive pulmonary disease\n* Active infection\n* Ongoing IPF treatments including investigational therapy, immunosuppressants, and cytokine modulating agents\n* History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months","40 Years","80 Years",{"count":21,"type":22},[25,59],"Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.",[140],"Idiopathic Pulmonary Fibrosis",[142,140,143,144],"Pulmonary Fibrosis","Lung Diseases","Respiratory Tract Diseases","2024-11-15",{"date":119,"type":40},{"date":148,"type":40},"2023-06-06",{"date":150,"type":22},"2027-12-31",{"name":46,"class":47},""]